CagriSema protocol
Cagrilintide + Semaglutide (CagriSema). Dosing on this page comes from a published human trial or an approved product label, cited below.
How CagriSema works
A fixed combination of an amylin analog and a GLP-1 agonist. The rationale is that the two act on separate satiety pathways, so the combination is studied for an effect neither reaches alone.
CagriSema dosing schedule
The REDEFINE programme escalates both components in parallel to 2.4 mg each. Because both sit in one vial at a fixed ratio, a single draw delivers both — the stack calculator handles that split.
| Phase | Amount | Frequency | Notes |
|---|---|---|---|
| Weeks 1–4 | 0.25 mg / 0.25 mg | Once weekly | Both components at the lead-in step. |
| Weeks 5–8 | 0.5 mg / 0.5 mg | Once weekly | |
| Weeks 9–12 | 1.0 mg / 1.0 mg | Once weekly | |
| Weeks 13–16 | 1.7 mg / 1.7 mg | Once weekly | |
| Week 17 onward | 2.4 mg / 2.4 mg | Once weekly | Maintenance for both components. |
Study length: 68 weeks in REDEFINE 1.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for CagriSema: Not stocked by our featured supplier.
Storage and stability
Reported effects
- Gastrointestinal effects consistent with both parent compounds.
- Still investigational — no approved label and no long-term safety record.
Sourcing CagriSema
Our featured supplier does not stock this compound, and we are not going to point you at a vendor we have not looked at. Use the COA checklist on whoever you do buy from, and check the batch number on the certificate against the vial you receive.
